Key result
A high rate of eGFR decline in hypertensive patients without baseline CKD was associated with a higher risk of cardiovascular events and death.
Why the study?
It was unknown whether the rate and intensity of eGFR decline were associated with cardiovascular risk and death in hypertensive patients with a baseline eGFR above 60 ml/minute/1.73 m2.
Does a high rate of eGFR decline (≥10% per year) increase the risk of cardiovascular events and death in hypertensive patients without baseline chronic kidney disease?
Cohort (n=2,516)
Does a high rate of eGFR decline (≥10% per year) increase the risk of cardiovascular events and death in hypertensive patients without baseline chronic kidney disease?
A rapid decline in eGFR (≥10% per year) identifies hypertensive patients without baseline CKD who are at significantly increased risk for cardiovascular events.
Answers are grounded in this paper and cite their sources.
Rapid eGFR decline may flag higher CV risk in non-CKD hypertension; hypothesis-generating for trajectory-based risk stratification.
BACKGROUND: Our objective of this study was to determine if rate of estimated glomerular filtration rate (eGFR) decline and its intensity was associated with cardiovascular risk and death in patients with hypertension whose baseline eGFR was higher than 60 ml/minute/1.73 m2. METHODS: This study comprised 2,516 patients with hypertension who had had at least 2 serum creatinine measurements over a 4-year period. An eGFR reduction of ≥10% per year has been deemed as high eGFR and a reduction in eGFR of less than 10% per year as a low decline. The end points were coronary artery disease, stroke, transitory ischemic accident, peripheral arterial disease, heart failure, atrial fibrillation, and death from any cause. Cox regression analyses adjusted for potentially confounding factors were conducted. RESULTS: A total of 2,354 patients with low rate of eGFR decline and 149 with high rate of eGFR decline were analyzed. The adjusted model shows that a -10% rate of eGFR decline per year is associated with a higher risk of the primary end point (HR 1.9; 95% CI 1.1-3.5; P = 0.02) and arteriosclerotic vascular disease (HR 2.2; 95% CI 1.2-4.2; P < 0.001) in all hypertensive groups. The variables associated to high/low rate of eGFR decline in the logistic regression model were serum creatinine (OR 3.35; P < 0.001), gender, women (OR 15.3; P < 0.001), tobacco user (OR 1.9; P < 0.002), and pulse pressure (OR 0.99; P < 0.05). CONCLUSIONS: A rate of eGFR decline equal to or higher than -10% per year is a marker of cardiovascular risk for patients with arterial hypertension without chronic kidney disease at baseline. It may be useful to consider intensifying the global risk approach for these patients.
No takes yet. Share an insight, caveat, or question.
Tuero et al. (2019) conducted a cohort in Hypertension without chronic kidney disease (n=2,516). High rate of eGFR decline (≥10% per year) vs. Low rate of eGFR decline (<10% per year) was evaluated on Coronary artery disease, stroke, transitory ischemic accident, peripheral arterial disease, heart failure, atrial fibrillation, and death from any cause (HR 1.9, 95% CI 1.1-3.5, p=0.02). A high rate of eGFR decline in hypertensive patients without baseline CKD was associated with a higher risk of cardiovascular events and death.
Synapse has enriched 10 related papers. Consider them for comparative context: